|
RADFORD, Va., Nov. 23 /PRNewswire-FirstCall/ -- New River Pharmaceuticals
Inc. (Nasdaq: NRPH) announced today that it plans to present at the First
Albany Capital Annual Growth Conference on December 7, 2005 at 1:20 P.M. ET in
New York City.
R.J. Kirk, Chairman and Chief Executive Officer, and Krish Krishnan, Chief
Financial and Chief Operating Officer, of New River Pharmaceuticals, will
provide a corporate overview and update on the Companys clinical and
preclinical programs.
About New River
New River Pharmaceuticals Inc. is a specialty pharmaceutical company
focused on developing novel pharmaceuticals that are generational improvements
of widely prescribed drugs in large and growing markets.
For further information on New River, please visit the Companys Web site
at http://www.nrpharma.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995
This press release contains certain forward-looking information that is
intended to be covered by the safe harbor for "forward-looking statements"
provided by the Private Securities Litigation Reform Act of 1995. Forward-
looking statements are statements that are not historical facts. Words such as
"expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and
similar expressions are intended to identify forward-looking statements. These
statements include, but are not limited to, financial projections and
estimates and their underlying assumptions; statements regarding plans,
objectives and expectations with respect to future operations, products and
services; and statements regarding future performance. Such statements are
subject to certain risks and uncertainties, many of which are difficult to
predict and generally beyond the control of New River Pharmaceuticals, that
could cause actual results to differ materially from those expressed in, or
implied or projected by, the forward-looking information and statements. These
risks and uncertainties include: those discussed and identified in the New
River Pharmaceuticals Inc. annual report on Form 10-K, filed with the SEC on
April 1, 2005; the timing, progress and likelihood of success of our product
research and development programs; the timing and status of our preclinical
and clinical development of potential drugs; the likelihood of success of our
drug products in clinical trials and the regulatory approval process; our drug
products efficacy, abuse and tamper resistance, onset and duration of drug
action, ability to provide protection from overdose, ability to improve
patients symptoms, incidence of adverse events, ability to reduce opioid
tolerance, ability to reduce therapeutic variability, and ability to reduce
the risks associated with certain therapies; the ability to develop,
manufacture, launch and market our drug products; our projections for future
revenues, profitability and ability to achieve certain sales targets; our
estimates regarding our capital requirements and our needs for additional
financing; the likelihood of obtaining favorable scheduling and labeling of
our drug products; the likelihood of regulatory approval under Section
505(b)(2) under the Federal Food, Drug, and Cosmetic Act; our ability to
develop safer and improved versions of widely-prescribed drugs using our
Carrierwave (TM) technology; and our ability to obtain favorable patent
claims. Readers are cautioned not to place undue reliance on these forward-
looking statements that speak only as of the date hereof. New River
Pharmaceuticals does not undertake any obligation to republish revised
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. Readers are also
urged to carefully review and consider the various disclosures in New River
Pharmaceuticals annual report on Form 10-K, filed with the SEC on April 1,
2005, as well as other public filings with the SEC.
Contacts:
The Ruth Group
John Quirk (investors)
646-536-7029
jquirk@theruthgroup.com
Zack Kubow (media)
646-536-7020
zkubow@theruthgroup.com
|
|
